Early Phase 1 N=13 Treatment of HFpEF With Nitrate Supplement
Heart Failure With Normal Ejection Fraction
Primary: Time on Treadmill — 402.8; 181.2 seconds
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=32 Premature Fatigue in Veterans With Heart Failure: Neuronal Influences
Heart Failure
Primary: Maximal Voluntary Quadriceps Force [% Change From Baseline] — -30; -5 percentage change
Early Phase 1 N=48 The Effects of Buprenorphine on Responses to Verbal Tasks
Basic Science
Primary: Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Subscales of the Drug Effects Questionnaire Subjective Responses to…
Early Phase 1 N=62 Translating Extinction Research to Improve Pharmacotherapy for Tobacco Dependence
Smoking Cessation · Tobacco Dependence
Primary: Rate of Participant Retention — 15; 16; 19 Participants
Early Phase 1 N=12 Ivermectin and Human Immunity
Ivermectin
Primary: The Number of Cytokines Showing Statistically Significant Changes From Pre-treatment Levels Will be Recorded. — 0; 0; 0; 0 Cytokines changed from t=0
Early Phase 1 N=6 Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women
Human Immunodeficiency Virus (HIV) Prophylaxis
Primary: Number of Participants With Specific Graded Adverse Events in Single, Dual, and Triple Antiretroviral (ARV) Intravaginal Rings (IVRs) — 4; 1; 4; 1 participants
Early Phase 1 N=20 Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin
Deep-Venous Thrombosis · Pulmonary Embolism · Venous Thromboembolism
Primary: Number of Participants With Anti-Xa Levels Within Target Range (0.1-0.35 IU/mL) — 0; 12 Participants
Early Phase 1 N=8 Safety and Pharmacokinetics of Sustained-release Depot Tacrolimus: A First-in-human Study
Organ Transplant Rejection · Psoriasis
Primary: Number of Subjects That Experienced Treatment-related Adverse Events [Safety and Tolerability] — 6; 6; 3; 2 Participants
Early Phase 1 N=16 Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma
Carcinoma, Renal Cell
Primary: Number of Grade 3 or 4 Adverse Events — 5; 0 adverse events
Early Phase 1 N=76 Autonomic Neuropathy, GI Motility, and Inflammation in HIV
HIV Disease
Primary: Change in Breath Test — 28; 14 ppm
Early Phase 1 N=8 Progesterone for Cannabis Withdrawal
Cannabis Use Disorder · Cannabis Withdrawal
Primary: Change in Salivary Progesterone Level — 237.86; 97.87 pg/ml
Early Phase 1 N=9 Impact of a Non-Drug Choice on Cocaine Reinforcement
Cocaine Dependence
Primary: The Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 2.75; 1.38; 1.38; 4.75 cocaine choices
Early Phase 1 N=12 Role of Methane in Glycemic Control
Diabetes · Obesity
Primary: Number of Subjects Who Eradicated Methane on Breath Test — 8 participants
Early Phase 1 N=33 Aqueous Humor Dynamics and Brimonidine
Intraocular Pressure
Primary: Seated Day-time IOP 9 am and 11 am, Supine Day-time IOP 9 am and 11 am, and Seated Night-time IOP 9 pm and 11 pm — 18.1; 20.3; 18.0; 19.9 mmHg
Early Phase 1 N=83 Conversations as a Means to Delay the Onset of Alzheimer's Disease
Mild Cognitive Impairment · Cognitive Change
Primary: Changes in Global Cognitive Function Using Mini Mental State Examination Score (Post-study Test Score - Baseline Test Score) — -0.51; -0.07 score on a scale — p=0.25